🇺🇸 FDA
Pipeline program

ATI-1013 (0.2 g)

ATI-1013-001

Phase 1 mab active

Quick answer

ATI-1013 (0.2 g) for Thromboangiitis Obliterans (Buerger's Disease) is a Phase 1 program (mab) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Thromboangiitis Obliterans (Buerger's Disease)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials